Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
72 results about "Zinc binding" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Quinazoline based EGFR inhibitors containing a zinc binding moiety
InactiveUS20080139590A1Enhanced and unexpected propertyHigh activityOrganic active ingredientsBiocideDiseaseZinc binding
The present invention relates to quinazoline containing zinc-binding moiety based derivatives that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
Owner:CURIS INC
Assay
ActiveUS20060030050A1Improve bindingComponent separationDisease diagnosisBinding domainMicroparticle
Compositions and assay methods for and relating to the detection of glycated hemoglobin are provided. In particular, the presence and level of glycated hemoglobin can be detected in a blood sample. The compositions comprise microparticles which have zinc coating for use in the improved binding of proteins exhibiting a zinc binding domain, in particular glycated hemoglobin.
Owner:AXIS SHIELD DIAGNOSTICS
HSP90 Inhibitors Containing a Zinc Binding Moiety
InactiveUS20080234297A1Enhanced and unexpected propertyEffective for treating diseaseBiocideOrganic chemistryHsp InhibitorZinc binding
Owner:CURIS INC
Vegfr inhibitors containing a zinc binding moiety
InactiveUS20090076044A1Enhanced and unexpected propertyEffective for treating diseaseBiocideSenses disorderZinc bindingHDAC inhibitor
Owner:CURIS INC
Zinc binding compounds and their method of use
InactiveUS20050250214A1Efficient ConcentrationAnalysis using chemical indicatorsOrganic chemistryMetal chelateZinc binding
The present invention provides a metal chelator and methods that facilitate binding, detecting, monitoring and quantitating of zinc ions in a sample. The metal chelating moiety of the zinc-binding compound is an analog of the well-known calcium chelator, BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N′N′-tetraacetic acid), wherein the chelating moiety has been modified from a tetraacetic acid moiety to a tri- di- or monoacetic moiety. This change in acetic acid groups on the metal chelating moiety results in the selective bindings of zinc ions in the presence of calcium ions, both of which are present in biological fluids and intracellular cytosolic fluid and organelles.
Owner:MOLECULAR PROBES
Quinazoline based EGFR inhibitors containing a zinc binding moiety
InactiveUS20080194578A1Enhanced and unexpected propertyHigh activityOrganic active ingredientsBiocideDiseaseZinc binding
The present invention relates to quinazoline containing zinc-binding moiety based derivatives that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
Owner:CURIS INC
Raf kinase inhibitors containing a zinc binding moiety
InactiveUS20080234332A1Enhanced and unexpected propertyEffective for treating diseaseBiocideOrganic chemistryRaf Kinase InhibitorDisease
The present invention relates to Raf kinase inhibitors containing zinc-binding and their use in the treatment of Raf related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
Owner:CURIS INC
Tyrosine kinase inhibitors containing a zinc binding moiety
InactiveUS20080125440A1Effective for treating diseaseHigh activityOrganic active ingredientsBiocideDiseaseTyrosine-kinase inhibitor
Owner:CURIS INC
Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
ActiveUS20100222343A1Effective for treating diseaseHigh activityBiocideOrganic active ingredientsHistone deacetylaseZinc binding
The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
Owner:CURIS INC
CDK inhibitors containing a zinc binding moiety
InactiveUS8563741B2Effective for treating diseaseHigh activityBiocideOrganic chemistryZinc bindingHDAC inhibitor
Owner:CURIS INC
Quinazoline based EGFR inhibitors containing a zinc binding moiety
InactiveUS7547781B2Enhanced and unexpected propertyHigh activityOrganic active ingredientsBiocideDiseaseZinc binding
Owner:CURIS INC
Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
ActiveUS8367663B2Effective for treating diseaseHigh activityBiocideNervous disorderDiseaseHistone deacetylase
The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
Owner:CURIS INC
Medical cold compress patch and preparation method thereof
InactiveCN108210887ALong-lasting and uniform coolingImprove cooling effectOrganic active ingredientsSenses disorderWater basedBiocompatibility Testing
The invention relates to a medical cold compress patch and a preparation method thereof. The medical cold compress patch is prepared from the following components in percentage by mass: 0.05-0.2% of sodium hyaluronate, 0.002-0.2% of epidermal growth factor, 0.005-0.1% of zinc-binding metallothionein, 3-6% of aloe extract, 1-4% of vitamin E, 1-5% of glycerin, 0.2-0.4% of phenoxyethanol, 0.2-0.4% ofethylhexylglycerin, 0.1-0.3% of Carbomer 940, 0.08-0.2% of triethanolamine and the balance of deionized water based on 100%. The medical cold compress patch has the following advantages: (1) the cooling is uniform, lasting and mild; (2) the biocompatibility is high, and stimulation or toxic or side effects are avoided; (3) at the time of cold compress, an effect of repairing the damaged skin tissues is realized; the medical cold compress patch is safe and convenient to use; (4) unwell symptoms of closed soft tissues are relieved, including soft tissue sprain, contusion, cold compress paint after laser cosmetic surgery, eye fatigue, and the like.
Owner:NANJING TZONE BIOLOGICAL SCI & TECH
Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
ActiveUS20120088764A1Effective for treating diseaseHigh activityOrganic active ingredientsNervous disorderDiseaseHistone deacetylase
The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
Owner:CURIS INC
Cdk inhibitors containing a zinc binding moiety
InactiveUS20090093507A1Enhanced and unexpected propertyEffective for treating diseaseBiocideOrganic chemistryZinc bindingHDAC inhibitor
Owner:CURIS INC
Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
InactiveUS20080161320A1Effective for treating diseaseHigh activityBiocideOrganic active ingredientsDiseasePTK Inhibitors
The present invention relates to fused bicyclic pyrimidine containing zinc-binding moiety based derivatives that have unique properties as protein tyrosine kinase (PTK) inhibitors and their use in the treatment of PTK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
Owner:CURIS INC
Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety
InactiveUS20080125478A1Effective for treating diseaseHigh activityBiocideOrganic chemistryDiseasePTK Inhibitors
The present invention relates to substituted 2-indolinone containing zinc-binding moiety based derivatives that have enhanced or unique properties as inhibitors of protein tyrosine kinase (PTK) receptors and their use in the treatment of PTK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
Owner:CURIS INC
Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
ActiveUS8710219B2Maintain good propertiesPotent antiproliferative activityOrganic active ingredientsOrganic chemistryHistone deacetylaseZinc binding
Owner:CURIS INC
Zinc binding compounds and their method of use
Owner:LIFE TECH CORP
Zinc binding group-containing irreversible EGFR tyrosine kinase inhibitor
ActiveCN103965119AGood antitumor activityDelay drug resistanceOrganic active ingredientsOrganic chemistryEGFR Tyrosine Kinase InhibitorsTyrosine-kinase inhibitor
Belonging to the technical field of medicine, the invention in particular relates to a zinc binding group-containing irreversible EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor shown as general formula (I), its deuterated compounds, pharmaceutically acceptable salts or stereoisomers, wherein R1, R2, R3, R4, R5, R6, R7, W, X, L, T, and n are defined as the specification. The invention also relates to a preparation method of the compounds, pharmaceutical preparations containing the compounds, and application of the compounds in preparation of drugs treating and / or preventing tumors. (formula I).
Owner:BEIJING AOHE DRUG RES INST
Polyenolic zinc-binding agents (pezbins) actively promote inactivation of cancer stem cells and potentiate cytotoxic Anti-tumor drug substances
ActiveUS20150150834A1Inhibition of differentiationInhibit growthOrganic active ingredientsBiocideCancer cellOncology drugs
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK +1
Metalloprotein Inhibitors
Owner:RGT UNIV OF CALIFORNIA
Hsp90 inhibitors containing a zinc binding moiety
InactiveUS20090076006A1Effective for treating diseaseHigh activityBiocideOrganic chemistryHsp InhibitorZinc binding
Owner:CURIS INC
Treatment of inflammatory, autoimmune, or other disorders, using agents that reduce the sequestering of zinc by calprotectin
InactiveUS20070275095A1Reduce activity levelReduce concentrationBiocideNervous disorderDiseaseWhole body
Treatments are disclosed for inflammatory, autoimmune, or other disorders characterized by excessive activity of calprotectin, a protein that normally defends against microbial infections by sequestering available zinc, at a site of infection. Excessive calprotectin activity, which can cause zinc deficiencies in localized tissues, can create or aggravate various disorders. However, ingestion of systemic (oral) zinc supplements tends to activate offsetting mechanisms, and such supplements therefore usually are ineffective. Accordingly, targeted treatments are disclosed herein for suppressing and controlling excessive calprotectin activity, in local tissues. Such methods include targeted injections of zinc solutions, and plasmapheresis treatment. Screening tests also are described for identifying non-protein drugs that can either (i) bind specifically to the zinc-binding sites of calprotectin, or (ii) suppress the release of calprotectin by neutrophil cells.
Owner:KOSSOR DAVID C
Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
ActiveUS20130090335A1Maintain good propertiesPotent antiproliferative activityOrganic active ingredientsOrganic chemistryHistone deacetylaseZinc binding
The invention provides a compound of Formula I,Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
Owner:CURIS INC
Method for increasing the stability and intensity of odorant molecules
InactiveUS20050096852A1Increased zinc-binding abilityImprove stabilityCosmetic preparationsToilet preparationsCompound (substance)Zinc binding
Methods for determining determinants of an odorant, such as character, intensity and stability, are described. Odorant character is determined based on the vibrational spectra of the odorant, odor intensity is determined based on zinc-binding affinity, and stability is based on an analysis of the odorant in a particular environment. The methods described herein permit one to design novel odorant molecules with increased zinc-binding ability, with all other things such as size volatility and hydrophobicity being equal, to increase the intensity of an odorant derivative relative to a parent odorant from which it is derived. Combinatorial libraries of odorants (“odotopic libraries”) to be evaluated for odor character and intensity are also disclosed, as are high throughput methods of evaluating these compounds. Further, methods for identifying an odorant with similar odor character but with improved intensity, stability or other improved physical and / or chemical properties are disclosed.
Owner:FLEXITRAL INC
Polyenolic zinc-binding agents (pezbins) actively promote inactivation of cancer stem cells and potentiate cytotoxic anti-tumor drug substances
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK +1
Raf kinase inhibitors containing a zinc binding moiety
Owner:CURIS INC
Quinazoline based EGFR inhibitors containing a zinc binding moiety
InactiveUS20140221403A1Enhanced and unexpected propertyHigh activityBiocideOrganic active ingredientsDiseaseTyrosine
Owner:CURIS INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com